Tech Company Financing Transactions
Uniquity Bio Funding Round
On 5/15/2024, Uniquity Bio secured $300 million in Series C funding from Blackstone.
Transaction Overview
Company Name
Announced On
5/15/2024
Transaction Type
Venture Equity
Amount
$300,000,000
Round
Series C
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1200 Atwater Drive 105
Malvern, PA 19355
USA
Malvern, PA 19355
USA
Phone
Website
Email Address
Overview
At Uniquity Bio, we bring decades of experience from the world's top pharmaceutical companies and research institutions into the rigorous -- yet nimble -- development of exciting, high-potential medicines. As scientific advancements in the field of immunology and inflammation have rapidly expanded, so has the opportunity to deliver unprecedented benefits to people suffering from chronic and prevalent immune-mediated diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Stephen Tullman
Chief Executive Officer
Brian Lortie
Chief Financial Officer
Daniel Rudio
Chief Medical Officer
Tim Henkel
Chief Scientific Officer
Hector Ortega
VP - General Counsel
Yves Quintin
VP - Manufacturing
Bret Shirley
VP - Regulatory Affairs
Jiten Rana
Browse more venture capital transactions:
Prev: 5/15/2024: Kings League venture capital transaction
Next: 5/15/2024: Alkira venture capital transaction
Share this article
News on VC Transactions
We do our best to record every notable VC transaction. VC transactions on this site come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs